Can lithium be used for hyperthyroidism, and what are the specific indications, recommended dosing, and necessary monitoring?

Lithium for Hyperthyroidism: Adjunctive Use in Radioactive Iodine Therapy

Lithium is not a primary treatment for hyperthyroidism but serves as an adjunct to radioactive iodine (RAI) therapy by increasing thyroidal iodine retention and reducing thyroid hormone release, particularly useful in severe hyperthyroidism or when RAI efficacy needs enhancement. 1, 2

Mechanism of Action and Rationale

• Lithium inhibits thyroid hormone release from the thyroid gland by blocking the proteolysis of thyroglobulin, making it useful as adjunctive therapy in severe hyperthyroidism 2
• Lithium increases thyroidal radioiodine retention without reducing iodide uptake, thereby increasing the radiation dose delivered to the thyroid when administered with RAI 1, 3
• The drug prolongs intrathyroidal retention of RAI, which is considered an important determinant of RAI therapeutic effectiveness 3

Specific Clinical Indications

As Adjunct to RAI Therapy

• Observational studies demonstrate significant improvement in cure rates when lithium is added to RAI (odds ratio 1.92; 95% CI 1.24-2.96), though interventional trials showed non-significant improvement (OR 1.28; 95% CI 0.85-1.91) 1
• Adjunctive lithium reduces time to cure and blunts thyroid hormone excursions after RAI administration 1
• Lithium priming increases the radioiodine retention index significantly in patients with diffuse toxic goiter and results in reduced serum FT4 levels 3

Management of Severe Hyperthyroidism

• Lithium can be used as adjunct therapy in the management of severe hyperthyroidism due to its ability to inhibit thyroid hormone release 2
• The drug may help reduce administered RAI activity while maintaining therapeutic efficacy, with potential implications for cost reduction and radiation safety 3

Recommended Dosing Protocol

Short-Course Lithium Priming Regimen

• Administer 900 mg lithium per day in three divided doses orally for 4-7 days before and continuing 5 days after RAI therapy 3
• Check serum lithium level on day 4 after starting therapy to ensure levels remain in safe range (target approximately 0.6 mEq/L) 3
• This low-dose protocol has been found feasible and safe, with mean serum lithium concentration of 0.6 mEq/L 3

Monitoring Requirements

• Assess baseline renal and liver function before initiating lithium, as the drug is excreted principally through glomerular filtration and proximal tubule function 4
• Monitor serum lithium levels during therapy, keeping levels below 1.5 mEq/L to avoid toxicity 3
• Regular monitoring of thyroid function tests is necessary during lithium therapy 5

Critical Safety Considerations and Contraindications

Black Box Warning

• Lithium toxicity is closely related to serum lithium concentrations and can occur at doses close to therapeutic concentrations; facilities for prompt and accurate serum lithium determinations must be available before initiating therapy 5
• Based on animal studies, lithium may cause fetal harm, and human studies suggest fetal harm but are insufficient to determine risk 5

Thyroid-Specific Risks

• Lithium commonly causes goiter in up to 40% of patients and hypothyroidism in approximately 20% of long-term users 2
• Lithium increases thyroid autoimmunity if present before therapy 2
• Paradoxically, lithium can also cause hyperthyroidism due to thyroiditis or rarely Graves' disease, though this is less common than hypothyroidism 6, 4

Drug-Thyroid Interactions

• Hyperthyroidism alters renal tubular function and may result in retention of lithium and systemic toxicity through induction of the proximal tubule sodium-hydrogen antiporter 4
• Thyroxine affects tubular function and alters lithium clearance such that thyroid disease may cause lithium retention and subsequent toxicity 4
• In lithium-treated patients with biochemical hyperthyroidism, early antithyroid treatment may be appropriate to prevent lithium toxicity 4

Common Pitfalls and How to Avoid Them

Masking of Hyperthyroid Signs

• Lithium therapy may mask the clinical signs of hyperthyroidism by inducing cellular unresponsiveness to thyroid hormones, even when biochemical hyperthyroidism is present 4
• Do not rely solely on clinical symptoms to assess thyroid status in lithium-treated patients; always obtain biochemical confirmation 4

Thyroid Storm Risk

• One case report documented thyroid storm following dialysis to remove lithium in a hyperthyroid patient, highlighting the need for early antithyroid medication when hyperthyroidism is detected 4
• Consider initiating antithyroid drugs before attempting lithium removal in hyperthyroid patients with lithium toxicity 4

Side Effect Management

• Lithium-related side effects in the context of RAI therapy are infrequent and usually mild 1
• Most common adverse effects include tremor, polyuria-polydipsia, diarrhea, and subclinical hypothyroidism 5
• Headache may occur, necessitating dose reduction in some patients 3

Evidence Quality and Limitations

• The observational trials showing benefit are retrospective cohort studies (N=851), while interventional trials (N=485) did not reach statistical significance due to the effect of a single large negative trial 1
• The overall quality of evidence for lithium in Kleine-Levin syndrome (a different indication) was rated as very low due to imprecision, though no serious adverse events were reported 5
• More research is required on the cellular proliferative effects of lithium and its impact on the immune system in thyroid disease 2

Patient Populations Requiring Modified Approach

Pregnant or Breastfeeding Women

• The balance of risks and harms is likely different for pregnant and breastfeeding women due to potential fetal harm 5
• Lithium should be avoided in pregnancy unless absolutely necessary, given animal and human data suggesting fetal harm 5

Patients with Renal Impairment

• Lithium excretion relates principally to glomerular filtration rate and proximal tubule function, requiring dose adjustment or avoidance in renal impairment 4

Patients with Pre-existing Thyroid Autoimmunity

• Lithium increases thyroid autoimmunity if present before therapy, requiring closer monitoring in these patients 2